Randomized crossover clinical trial of coenzyme Q10 and nicotinamide riboside in chronic kidney disease

Objective

To examine the effects of NR and coenzyme Q10 (CoQ10) supplementation alone for six weeks on physical endurance, work efficiency, and metabolic profile in chronic kidney disease (CKD) patients.

Study Design

Randomized double-blind, placebo-controlled, crossover study in 25 chronic kidney disease (CKD) patients

Dose

1000 mg NR or 1200 mg CoQ10

Duration

6 weeks

Key Outcomes

  • NR supplementation showed a trend towards improved energy metabolism and submaximal exercise efficiency, suggesting better carbohydrate utilization for energy.

  • NR decreased plasma levels of NAD-dependent citric acid cycle intermediates, suggesting improved mitochondrial metabolism.

  • NR reduced short and medium-chained plasma triglycerides with a high degree of saturation (tightly packed), suggesting favorable changes in lipid metabolism.

  • CoQ10 reduced certain types of triglycerides and increased plasma free fatty acids.

Clinical, Metabolic HealthANAD StaffMetabolic Health